Recent Analysts’ Ratings Changes for BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (NASDAQ: BMRN) recently received a number of ratings updates from brokerages and research firms:

• 7/14/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by UBS Group AG.
• 7/14/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright.
• 7/7/2026 – BioMarin Pharmaceutical had its price target lowered by Royal Bank Of Canada from $66.00 to $62.00. They now have a “sector perform” rating on the stock.
• 6/26/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 6/22/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright.
• 6/11/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 6/6/2026 – BioMarin Pharmaceutical was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/29/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/23/2026 – BioMarin Pharmaceutical was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/22/2026 – BioMarin Pharmaceutical had its price target lowered by Canaccord Genuity Group Inc. from $116.00 to $111.00. They now have a “buy” rating on the stock.
• 5/19/2026 – BioMarin Pharmaceutical had its price target lowered by Bank of America Corporation from $85.00 to $80.00. They now have a “buy” rating on the stock.
• 5/19/2026 – BioMarin Pharmaceutical is now covered by Citigroup Inc.. They set a “buy” rating and a $75.00 price target on the stock.
• 5/18/2026 – BioMarin Pharmaceutical was upgraded by Citigroup Inc. to “strong-buy”.
• 5/18/2026 – BioMarin Pharmaceutical had its price target lowered by HC Wainwright from $55.00 to $50.00. They now have a “neutral” rating on the stock.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 3,281 shares of the stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $53.85, for a total transaction of $176,681.85. Following the completion of the sale, the executive vice president owned 51,818 shares of the company’s stock, valued at $2,790,399.30. This represents a 5.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is owned by corporate insiders.

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.